VCAM1 and atherosclerosis: This study employs a series of in vitro assays modelling pathological monocyte recruitment during vascular inflammation to preliminarily evaluate the therapeutic potential of seven novel anti-VCAM-1 monoclonal antibodies (mAbs) as possible drug candidates for atherosclerosis.